Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patients
    • Disease patterns
    • Diagnostics
    • Therapy
  • Partner Content
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
  • Departments
    • Allergology and clinical immunology
    • General Internal Medicine
    • Anesthesiology
    • Angiology
    • Surgery
    • Dermatology and venereology
    • Endocrinology and Diabetology
    • Nutrition
    • Gastroenterology and Hepatology
    • Genetics
    • Geriatrics
    • Gynecology
    • Hematology
    • Infectiology
    • Cardiology
    • Nephrology
    • Neurology
    • Emergency and intensive care medicine
    • Nuclear Medicine
    • Oncology
    • Ophthalmology
    • ORL
    • Orthopedics
    • Pediatrics
    • Pharmacology and toxicology
    • Pharmaceutical medicine
    • Phlebology
    • Physical medicine and rehabilitation
    • Pneumology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Radiology
    • Forensic Medicine
    • Rheumatology
    • Sports Medicine
    • Traumatology and trauma surgery
    • Tropical and travel medicine
    • Urology
    • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
  • Log In
  • Register
  • My account
  • Contact
  • Publications
  • Contact
  • Deutsch
  • English
  • Français
  • Italiano
  • Português
  • Español
Subscribe
Medizinonline Medizinonline
Medizinonline Medizinonline
  • News
    • News
    • Market & Medicine
  • Patienten
    • Krankheitsbilder
    • Diagnostik
    • Therapie
  • Partner Content
    • Diabetes
      • Dia-Month Club – Type 2 Diabetes
      • Diabetes in Motion
      • Diabetes Podcasts
    • Gastroenterology
      • IBD matters
    • Oncology
      • Swiss Oncology in motion
    • Orthopedics
      • Osteoporosis in motion
    • Phytotherapie
    • Rheumatology
  • Departments
    • Fachbereiche 1-13
      • Allergology and clinical immunology
      • General Internal Medicine
      • Anesthesiology
      • Angiology
      • Surgery
      • Dermatology and venereology
      • Endocrinology and Diabetology
      • Nutrition
      • Gastroenterology and Hepatology
      • Genetics
      • Geriatrics
      • Gynecology
      • Hematology
    • Fachbereiche 14-26
      • Infectiology
      • Cardiology
      • Nephrology
      • Neurology
      • Emergency and intensive care medicine
      • Nuclear Medicine
      • Oncology
      • Ophthalmology
      • ORL
      • Orthopedics
      • Pediatrics
      • Pharmacology and toxicology
      • Pharmaceutical medicine
    • Fachbereiche 26-38
      • Phlebology
      • Physical medicine and rehabilitation
      • Phytotherapy
      • Pneumology
      • Prevention and health care
      • Psychiatry and psychotherapy
      • Radiology
      • Forensic Medicine
      • Rheumatology
      • Sports Medicine
      • Traumatology and trauma surgery
      • Tropical and travel medicine
      • Urology
      • Dentistry
  • CME & Congresses
    • CME continuing education
    • Congress Reports
    • Congress calendar
  • Practice
    • Noctimed
    • Practice Management
    • Jobs
    • Interviews
Login

Sie haben noch keinen Account? Registrieren

  • Multiple sclerosis

From “one size fits all” to personalized therapy

    • Congress Reports
    • Neurology
    • RX
  • 2 minute read

Multiple sclerosis is also called a disease with a thousand faces, because no two courses are alike. Early intervention is needed to preserve brain and spinal cord tissue. This is because even in the early stages, mental well-being, quality of life and ability to work, among other things, can be significantly impaired. The goal is personalized medicine that focuses on individual concerns.

Hippocrates already knew that it is much more important which patient has the disease than which disease the patient has. Nevertheless, for many years the principle of “one size fits all” was applied and multiple sclerosis (MS) was regarded as a target, as Prof. Tjalf Ziemssen, MD, Dresden (D), pointed out. The foundation of evidence-based medicine also does not leave much room for individual decision-making. This is because a statistical approach requires large numbers to produce representative results. However, MS is an individually very variable disease with different courses. Therefore, the therapy should actually be adapted to this variability, i.e., personalized, according to the expert. However, the disease is difficult to monitor and predict. This makes it all the more important in daily practice to keep the peculiarities of each patient in mind and to phenotype them by measurement (Fig. 1).

 

 

Phenotypes in focus

Lublin MS phenotyping has taken a first step in the right direction by distinguishing the disease into active and non-active patients. However, against the backdrop of the many therapeutic options available today, this is no longer sufficient. A much more sensitive system is needed to capture sub-clinical markers in addition to the obvious clinical signs, such as disability progression and relapses, among others. These include, for example, MRI pathology, brain atrophy, and neurofilament levels. “We need to try to collect data in clinical reality,” Ziemssen affirmed.

Preserve the neurological reserve

The top priority is to maintain “brain health” (Fig. 2). Any delay in diagnosis and optimal therapy increases the risk of unnecessary loss of physical and cognitive functions for the individual patient. Overall, there are three main recommendations to maintain neurological reserve or brain health:

  1. Delays in diagnosis and therapy initiation or optimization should be avoided,
  2. Disease activity should be monitored in detail and closely in order to implement a so-called treat to a target therapy concept,
  3. Robust scientific evidence from Real World data will be generated that can be used to optimize the treatment of individual MS patients.

 

 

Under these conditions, it is possible to personalize MS therapy, the expert is certain. There is no contradiction in collecting large amounts of data in order to provide individualized treatment. This is the only way to observe how different patients respond to different therapies and then generate the appropriate treatment with the help of statistical methods. “I am sure that personalized therapy is what we will be able to offer our patients as standard in a few years,” Ziemssen concluded.

Source: Alzheimer’s Association International Conference (AAIC) 2020

 

Literature:

  1. Giovannoni G, et al: Brain Health. No time to lose in multiple sclerosis. www.msbrainhealth.org

 

InFo NEUROLOGY & PSYCHIATRY 2020; 18(5): 18 (published 9/1/20, ahead of print).

Autoren
  • Leoni Burggraf
Publikation
  • InFo NEUROLOGIE & PSYCHIATRIE
Related Topics
  • Multiple sclerosis
Previous Article
  • Cancer medicine of the future

Car-T cell therapy and its application in practice

  • Education
  • Hematology
  • Oncology
  • RX
  • Studies
View Post
Next Article
  • Heart failure

Physical training in patients with HFrEF and HFpEF.

  • Cardiology
  • Education
  • General Internal Medicine
  • Geriatrics
  • RX
  • Sports Medicine
View Post
You May Also Like
View Post
  • 38 min
  • Psychological dependence on AI assistants, smartphones and short videos

Algorithms, avatars and the unburdened mind

    • RX
    • CME continuing education
    • Neurology
    • Pediatrics
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 8 min
  • Psychooncology

Communication as the key to therapy adherence

    • CME continuing education
    • Practice Management
    • RX
View Post
  • 12 min
  • The Brain and the Motivation to Eat

Why is it so hard to lose weight?

    • RX
    • CME continuing education
    • Endocrinology and Diabetology
    • General Internal Medicine
    • Nutrition
    • Pharmacology and toxicology
    • Prevention and health care
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 5 min
  • Omaveloxolone for Friedreich's Ataxia

Efficacy and Safety Studied Over 6 Years

    • Neurology
    • Congress Reports
    • Endocrinology and Diabetology
    • RX
    • Studies
View Post
  • 6 min
  • Psoriasis: therapy with biologics and TYK-2-i

Progress assessments based on current long-term and real-world data

    • RX
    • Congress Reports
    • Dermatology and venereology
    • Pharmacology and toxicology
    • Rheumatology
    • Studies
View Post
  • 4 min
  • Hypertension: the most important facts for daily practice

Early dual antihypertensive therapy is usually indicated

    • RX
    • Cardiology
    • Congress Reports
    • General Internal Medicine
View Post
  • 4 min
  • Escitalopram for anxiety disorders

Positive effect, but no immediate improvement in symptoms

    • RX
    • Education
    • Neurology
    • Pharmacology and toxicology
    • Psychiatry and psychotherapy
    • Studies
View Post
  • 4 min
  • Helicobacter pylori infection

Simplified dual therapy beats quadruple regimen

    • RX
    • Education
    • Gastroenterology and Hepatology
    • General Internal Medicine
    • Infectiology
    • Studies
  • IBD matters

    Zum Thema
Top CME content
  • 1
    Why is it so hard to lose weight?
  • 2
    Algorithms, avatars and the unburdened mind
  • 3
    Communication as the key to therapy adherence
  • 4
    Communication as the key to therapy adherence
  • 5
    Solutions to the malnutrition dilemma

Newsletter

Sign up and stay up to date

Subscribe
Medizinonline Medizinonline
  • Contact
  • General terms and conditions
  • Imprint

Input your search keywords and press Enter.